Tak Yee Tania Tai, MD
Glaucoma Specialist · Brooklyn, NYNPI 1568620300
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,173 of the $10,692 with a category attached, or 76.4%. 24 manufacturers reported payments, led by NEW World Medical,inc. at 29.9% of the total. Reporting peaked in 2024 at $4,041 and has fallen 52.4% since, to $1,922 in 2025.
Across 213 payments — averaging $50.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$3K
- AbbVie$2K
- Alcon$1K
- Bausch & Lomb Americas Inc.$690
- Aerie Pharmaceuticals, Inc.$641
- Glaukos Corporation$481
- plus $3K from 18 others
What the payments were for
- Speaking & faculty fees$2,50023%
- Food & beverage$8,17376%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 10 | $3,194 |
| AbbVie(2 entities) | 45 | $1,531 |
| Alcon | 23 | $1,411 |
| Bausch & Lomb Americas Inc. | 33 | $690 |
| Aerie Pharmaceuticals, Inc. | 12 | $641 |
| Glaukos Corporation | 4 | $481 |
| Sun Pharmaceutical Industries Inc. | 20 | $478 |
| Oyster Point Pharma, Inc. | 21 | $452 |
| Sight Sciences, Inc. | 5 | $405 |
| Novartis | 12 | $239 |
| Rayner Intraocular Lenses Limited | 1 | $205 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $192 |
| Apellis Pharmaceuticals, Inc. | 6 | $188 |
| Omeros Corporation | 1 | $118 |
| Alimera Sciences, Inc. | 4 | $87 |
| Tarsus Pharmaceuticals, Inc. | 3 | $67 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $61 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $60 |
| Mallinckrodt Hospital Products Inc. | 2 | $56 |
| Eyevance Pharmaceuticals LLC | 2 | $42 |
| Genentech USA, Inc. | 1 | $28 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$2,912
- Kahook Dual Blade$2,912
- Clearpath$2,799
- Streamline$2,799
- DURYSTA$655
- Rhopressa$511
- Clareon$438
- Rocklatan$367
- iStent inject Trabecular Micro-Bypass Stent System$285
- RAYNER CATARACT SET 1$205
- RayOne EMV$205
- RayOne Spheric$205
- RayOne Aspheric$205
- iDoseTR$151
- Centurion$150
- Hydrus Microstent$148
- OMNI(R) SURGICAL SYSTEM (US)$148
- LUMIGAN$144
- XEN GLAUCOMA TREATMENT SYSTEM$144
- ACTIVEFOCUS$127
How this compares
$10,692 in reported general payments places this provider in the 85th percentile of 35 glaucoma specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 351 | $177,830 |
| XiidraLifitegrast | 197 | $158,971 |
| RocklatanNetarsudil Mesylat/Latanoprost | 254 | $115,966 |
| CombiganBrimonidine Tartrate/Timolol | 321 | $107,947 |
| RhopressaNetarsudil Mesylate | 229 | $101,287 |
| RestasisCyclosporine | 125 | $98,220 |
| VyzultaLatanoprostene Bunod | 244 | $97,602 |
| Alphagan PBrimonidine Tartrate | 144 | $58,507 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 169 | $33,810 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 156 | $33,711 |
| CequaCyclosporine | 52 | $31,004 |
| Brimonidine Tartrate | 416 | $28,597 |
| TyrvayaVarenicline Tartrate | 35 | $22,522 |
| MieboPerfluorohexyloctane/Pf | 14 | $17,483 |
| Travoprost | 106 | $15,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P, Restasis Multidose | $1,531 | $452,444957 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $690 | $274,056455 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $641 | $217,252483 claims |
| AlconSimbrinza, Azopt | $1,411 | $39,449167 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $478 | $31,00452 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $452 | $22,52235 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax, Loteprednol Etabonate | $61 | $16,53054 claims |
| NovartisIlevro | $239 | $9,63924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 glaucoma specialist providers in New York.
Other glaucoma specialist in Brooklyn
- Jonathan SchulhofBrooklyn$73K
- Shayma JawadBrooklyn$3K
- Janet SerleNew York$103K
- Sarah VantasselNew York$76K
- Sonya DharNew York$19K
- Jacqueline LenociCommack$13K
- Leah UmfreyAlbany$6K
- Smitha VoletiYonkers$5K
- Yvonne OkakaNew York$5K
- Brian KrawitzBronx$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.